San Diego, United States
Zafrens, founded in 2022, is a pioneering therapeutics company headquartered in the United States. The company's slogan, "Opening doors to new insights at the interface of biology, chemistry and engineering," aptly reflects their vision of redefining drug discovery processes.
Zafrens has developed an ultra-high-throughput platform capable of isolating, culturing, imaging, and sequencing millions of cells daily. This proprietary technology offers comprehensive insights into diverse cell populations, enabling a detailed analysis of molecular profiles such as DNA, RNA, and proteins, in direct correlation with cell phenotype and function. Their mission is to exploit this technology to reveal all cellular stories, potentially expediting the drug discovery process.
In its recent funding round on 01 February 2025, Zafrens secured an $8.00M Series A investment from notable investors including Global Brain, Imec.xpand, Prime Movers Lab, and KOFA Healthcare Investments. This financial backing by key market players underscores confidence in Zafrens' innovative approach and growth potential.
